Pulmonary veno-occlusive disease: The bête noire of pulmonary hypertension in connective tissue diseases?

Presse Medicale

Volumn 40, Issue 1 PART2, 2011, Pages

  O'Callaghan, Dermot S ^a,b,c   Dorfmuller, Peter ^a,b,c   Jaïs, Xavier ^a,b,c   Mouthon, Luc ^d   Sitbon, Olivier ^a,b,c   Simonneau, Gérald ^a,b,c   Humbert, Marc ^a,b,c   Montani, David ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIURETIC AGENT; ANTINUCLEAR ANTIBODY; ANTIVITAMIN K; BOSENTAN; CENTROMERE ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ILOPROST; IMATINIB; PROSTACYCLIN; SILDENAFIL; VASODILATOR AGENT;

ANTICOAGULANT THERAPY; CONNECTIVE TISSUE DISEASE; CONTINUOUS INFUSION; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DIZZINESS; DOPPLER ECHOCARDIOGRAPHY; DRUG MEGADOSE; DYSPNEA; FATIGUE; HEART CATHETERIZATION; HEART PALPITATION; HEART RIGHT VENTRICLE FAILURE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; HYPOXEMIA; IMAGE ANALYSIS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LUNG ARTERY PRESSURE; LUNG DISEASE; LUNG EDEMA; LUNG HEMODYNAMICS; LUNG HEMORRHAGE; LUNG LAVAGE; LUNG TRANSPLANTATION; LUNG WEDGE PRESSURE; MIXED CONNECTIVE TISSUE DISEASE; PATHOGENESIS; PHYSICAL EXAMINATION; PREVALENCE; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; PULMONARY VENO-OCCLUSIVE DISEASE; RISK FACTOR; SCLERODERMA; SHORT SURVEY; SURVIVAL RATE; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THORAX DISEASE; THORAX RADIOGRAPHY; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 84866341576     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2010.10.017     Document Type: Short Survey

References (98)

1. Galiè N., Hoeper M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009, 34:1219-1263.
2. Galiè N., Hoeper M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30:2493-2537.
3. Palazzini M., Manes A. Pulmonary veno-occlusive disease misdiagnosed as idiopathic pulmonary arterial hypertension. Eur Respir Rev 2009, 18:177-180.
4. Dorfmuller P., Humbert M., Perros F., et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007, 38:893-902.
5. Frazier A., Franks T., Mohammed T., Ozbudak I., Galvin J. From the Archives of the AFIP: pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Radiographics 2007, 27:867-882.
6. Pietra G.G., Edwards W.D., Kay J.M., et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989, 80:1198-1206.
7. Jimenez S., Derk C. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004, 140:37-50.
8. Scussel-Lonzetti L., Joyal F., Raynauld J., et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002, 81:154-167.
9. Steen V., Medsger T. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944.
10. Steen V. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42.
11. Chang B., Schachna L., White B., Wigley F., Wise R. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006, 33:269-274.
12. Mayes M. Race, scleroderma, and survival: why is there a difference?. J Rheumatol 2005, 32:1873-1874.
13. Le Pavec J., Humbert M., Mouthon L., Hassoun P. Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2010, 181:1285-1293.
14. Hachulla E., Gressin V., Guillevin L., et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005, 52:3792-3800.
15. Hachulla E., de Groote P., Gressin V., et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009, 60:1831-1839.
16. Morassut P.A., Walley V.M., Smith C.D. Pulmonary veno-occlusive disease and the CREST variant of scleroderma. Can J Cardiol 1992, 8:1055-1058.
17. Dorfmuller P., Montani D., Humbert M. A walk on the far side of the lung - pulmonary venous involvement in patients suffering from systemic sclerosis-associated pulmonary arterial hypertension. Eur Respir J 2010, 35(1):6-8.
18. Simonneau G., Robbins I.M., Beghetti M., et al. Updated Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol 2009, 54:S43-54.
19. Rahman A., Isenberg D. Systemic lupus erythematosus. N Engl J Med 2008, 358:929-939.
20. Corrin B., Spencer H., Turner-Warwick M., Beales S., Hamblin J. Pulmonary veno-occlusion - an immune complex disease?. Virchows Arch A Pathol Anat Histol 1974, 364:81-91.
21. Lantuejoul S., Sheppard M.N., Corrin B., Burke M.M., Nicholson A.G. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006, 30:850-857.
22. Kishida Y., Kanai Y., Kuramochi S., Hosoda Y. Pulmonary venoocclusive disease in a patient with systemic lupus erythematosus. J Rheumatol 1993, 20:2161-2162.
23. Venables P. Mixed connective tissue disease. Lupus 2006, 15:132-137.
24. Burdt M., Hoffman R., Deutscher S., Wang G., Johnson J., Sharp G. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999, 42:899-909.
25. Zhang L., Visscher D., Rihal C., Aubry M. Pulmonary veno-occlusive disease as a primary cause of pulmonary hypertension in a patient with mixed connective tissue disease. Rheumatol Int 2007, 27:1163-1165.
26. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006, 173:1023-1030.
27. Montani D., Achouh L., Dorfmuller P., et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008, 87:220-233.
28. Bunte M.C., Patnaik M.M., Pritzker M.R., Burns L.J. Pulmonary veno-occlusive disease following hematopoietic stem cell transplantation: a rare model of endothelial dysfunction. Bone Marrow Transplant 2008, 41:677-686.
29. Gagnadoux F., Capron F., Lebeau B. Pulmonary veno-occlusive disease after neoadjuvant mitomycin chemotherapy and surgery for lung carcinoma. Lung Cancer 2002, 36:213-215.
30. Shahab N., Haider S., Doll D.C. Vascular toxicity of antineoplastic agents. Semin Oncol 2006, 33:121-138.
31. Mukai M., Kondo M., Bohgaki T., Notoya A., Kohno M. Pulmonary veno-occlusive disease following allogeneic peripheral blood stem cell transplantation for chronic myeloid leukaemia. Br J Haematol 2003, 123:1.
32. Swift G.L., Gibbs A., Campbell I.A., Wagenvoort C.A., Tuthill D. Pulmonary veno-occlusive disease and Hodgkin's lymphoma. Eur Respir J 1993, 6:596-598.
33. Ibrahim N.B., Burnley H., Gaber K.A., et al. Segmental pulmonary veno-occlusive disease secondary to lung cancer. J Clin Pathol 2005, 58:434-436.
34. Trobaugh-Lotrario A.D., Greffe B., Deterding R., Deutsch G., Quinones R. Pulmonary veno-occlusive disease after autologous bone marrow transplant in a child with stage IV neuroblastoma: case report and literature review. J Pediatr Hematol Oncol 2003, 25:405-409.
35. Seguchi M., Hirabayashi N., Fujii Y., et al. Pulmonary hypertension associated with pulmonary occlusive vasculopathy after allogeneic bone marrow transplantation. Transplantation 2000, 69:177-179.
36. Salzman D., Adkins D.R., Craig F., Freytes C., LeMaistre C.F. Malignancy-associated pulmonary veno-occlusive disease: report of a case following autologous bone marrow transplantation and review. Bone Marrow Transplant 1996, 18:755-760.
37. Canny G.J., Arbus G.S., Wilson G.J., Newth C.J. Fatal pulmonary hypertension following renal transplantation. Br J Dis Chest 1985, 79:191-195.
38. Jones R., Dawson A., Jenkins G., Nicholson A., Hansell D., Harrison N. Sarcoidosis-related pulmonary veno-occlusive disease presenting with recurrent haemoptysis. Eur Respir J 2009, 34:517-520.
39. Hamada K., Teramoto S., Narita N., Yamada E., Teramoto K., Kobzik L. Pulmonary veno-occlusive disease in pulmonary Langerhans' cell granulomatosis. Eur Respir J 2000, 15:421-423.
40. Hasleton P.S., Ironside J.W., Whittaker J.S., Kelly W., Ward C., Thompson G.S. Pulmonary veno-occlusive disease. A report of four cases. Histopathology 1986, 10:933-944.
41. Kokturk N., Demir N., Demircan S., et al. Pulmonary veno-occlusive disease in a patient with a history of Hashimoto's thyroiditis. Indian J Chest Dis Allied Sci 2005, 47:289-292.
42. Montani D., Price L.C., Dorfmuller P., et al. Pulmonary veno-occlusive disease. Eur Respir J 2009, 33:189-200.
43. Runo J.R., Vnencak-Jones C.L., Prince M., et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 2003, 167:889-894.
44. Aldred M.A., Vijayakrishnan J., James V., et al. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat 2006, 27:212-213.
45. Machado R.D., Aldred M.A., James V., et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006, 27:121-132.
46. Montani D., O'Callaghan D.S., Savale L., et al. Pulmonary veno-occlusive disease: recent progress and current challenges. Respir Med 2010, 104S1:S23-S32.
47. Langevitz P., Buskila D., Gladman D., Darlington G., Farewell V., Lee P. HLA alleles in systemic sclerosis: association with pulmonary hypertension and outcome. Br J Rheumatol 1992, 31:609-613.
48. Okawa-Takatsuji M., Aotsuka S., Fujinami M., Uwatoko S., Kinoshita M., Sumiya M. Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein. Clin Exp Immunol 1999, 116:174-180.
49. Stewart S., Rassl D. Advances in the understanding and classification of pulmonary hypertension. Histopathology 2009, 54:104-116.
50. Wagenvoort C.A., Wagenvoort N. The pathology of pulmonary veno-occlusive disease. Virchows Arch A Pathol Anat Histol 1974, 364:69-79.
51. Frazier A.A., Franks T.J., Cooke E.O., Mohammed T.L., Pugatch R.D., Galvin J.R. From the archives of the AFIP: pulmonary alveolar proteinosis. Radiographics 2008, 28:883-899. [quiz 915].
52. de Montpreville V., Dulmet E., Fadel E., Dartevelle P. Lymph node pathology in pulmonary veno-occlusive disease and pulmonary capillary heamangiomatosis. Virchows Archiv 2008, 453:171-176.
53. Montani D., Dorfmuller P., Maitre S., Jaïs X., Sitbon O., Simonneu G., et al. Maladie veino-occlusive et hémangiomatose capillaire pulmonaire. Presse Med 2010, 39:134-143.
54. Nicod P., Moser K. Primary pulmonary hypertension. The risk and benefit of lung biopsy. Circulation 1989, 80:1486-1488.
55. Montani D., O'Callaghan D.S., Jais X., et al. Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre. Eur Resp Rev 2009, 18:272-290.
56. Montani D., Savale L., Natali D., et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 2010, 31:1898-1907.
57. Resten A., Maitre S., Humbert M., et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 2004, 183:65-70.
58. Johnson S.R., Patsios D., Hwang D.M., Granton J.T. Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension. J Rheumatol 2006, 33:2347-2350.
59. Pepke-Zaba J. Diagnostic testing to guide the management of chronic thromboembolic pulmonary hypertension: state of the art. Eur Respir Rev 2010, 19:55-58.
60. Bailey C.L., Channick R.N., Auger W.R., et al. High probability perfusion lung scans in pulmonary venoocclusive disease. Am J Respir Crit Care Med 2000, 162:1974-1978.
61. Rabiller A., Jais X., Hamid A., et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J 2006, 27:108-113.
62. Dweik R., Arroliga A., Cash J. Alveolar hemorrhage in patients with rheumatic disease. Rheum Dis Clin North Am 1997, 23:395-410.
63. Holcomb B.W., Loyd J.E., Ely E.W., Johnson J., Robbins I.M. Pulmonary veno-occlusive disease: a case series and new observations. Chest 2000, 118:1671-1679.
64. Allanore Y., Borderie D., Avouac J., et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008, 58:284-291.
65. Hachulla E., Launay D., Mouthon L., et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis?. Chest 2009, 136:1211-1219.
66. Distler O., Pignone A. Pulmonary arterial hypertension and rheumatic diseases--from diagnosis to treatment. Rheumatology (Oxford) 2006, 45(Suppl. 4):iv22-25.
67. Mukerjee D., St George D., Knight C., et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004, 43:461-466.
68. Alam S., Palevsky H.I. Standard therapies for pulmonary arterial hypertension. Clin Chest Med 2007, 28:91-115.
69. Jaïs X., Bonnet D. Traitement de l'hypertension artérielle pulmonaire. Presse Med 2010, 39:22-32.
70. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334:296-302.
71. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000, 132:425-434.
72. Badesch D., McGoon M., Barst R., et al. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol 2009, 36:2244-2249.
73. Davis L., deBoisblanc B., Glynn C., Ramirez C., Summer W. Effect of prostacyclin on microvascular pressures in a patient with pulmonary veno-occlusive disease. Chest 1995, 108:1754-1756.
74. Palmer S.M., Robinson L.J., Wang A., Gossage J.R., Bashore T., Tapson V.F. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998, 113:237-240.
75. Montani D., Jaïs X., Price L., et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J 2009, 34:1348-1356.
76. Barboza C.E., Jardim C.V., Hovnanian A.L., Dias B.A., Souza R. Pulmonary veno-occlusive disease: diagnostic and therapeutic alternatives. J Bras Pneumol 2008, 34:749-752.
77. Barreto A.C., Franchi S.M., Castro C.R., Lopes A.A. One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease. Braz J Med Biol Res 2005, 38:185-195.
78. Creagh-Brown B.C., Nicholson A.G., Showkathali R., Gibbs J.S., Howard L.S. Pulmonary veno-occlusive disease presenting with recurrent pulmonary oedema and the use of nitric oxide to predict response to sildenafil. Thorax 2008, 63:933-934.
79. Hoeper M.M., Eschenbruch C., Zink-Wohlfart C., et al. Effects of inhaled nitric oxide and aerosolized iloprost in pulmonary veno-occlusive disease. Respir Med 1999, 93:62-64.
80. Overbeek M.J., van Nieuw Amerongen G.P., Boonstra A., Smit E.F., Vonk-Noordegraaf A. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J 2008, 32:232-235.
81. Kawut S., Taichman D., Archer-Chicko C., Palevsky H., Kimmel S. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003, 123:344-350.
82. Fisher M., Mathai S., Champion H., et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006, 54:3043-3050.
83. Humbert M., Simonneau G. Drug insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. Nat Clin Pract Rheumatol 2005, 1:93-101.
84. Overbeek M., Vonk M., Boonstra A., et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 2009, 34:371-379.
85. O'Callaghan D.S., Gaine S.P. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med 2007, 28:169-185.
86. Hoeper M.M., Markevych I., Spiekerkoetter E., Welte T., Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005, 26:858-863.
87. Montani D., Jais X., Dorfmuller P., Simonneau G., Sitbon O., Humbert M. Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution. Eur Respir J 2009, 34(5):1204-1206.
88. Hassoun P., Mouthon L., Barberà J., et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009, 54:S10-19.
89. Tanaka E., Harigai M., Tanaka M., Kawaguchi Y., Hara M., Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002, 29:282-287.
90. Morelli S., Giordano M., De Marzio P., Priori R., Sgreccia A., Valesini G. Pulmonary arterial hypertension responsive to immunosuppressive therapy in systemic lupus erythematosus. Lupus 1993, 2:367-369.
91. Jais X., Launay D., Yaici A., et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008, 58:521-531.
92. Mariette X., Brenot F., Brouet J. Recovery from pulmonary hypertension with steroid therapy in a patient with Sjögren's syndrome and polymyositis. J Rheumatol 1994, 21:772-773.
93. Gonzalez-Lopez L., Cardona-Muñoz E., Celis A., et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus 2004, 13:105-112.
94. Kamata Y., Nara H., Sato H., Masuyama J., Minota S., Yoshio T. Effect of steroid pulse therapy on mixed connective tissue disease with pulmonary arterial hypertension. Ann Rheum Dis 2005, 64:1236-1237.
95. Sanchez O., Sitbon O., Jais X., Simonneau G., Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006, 130:182-189.
96. Orens J., Estenne M., Arcasoy S., et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006, 25:745-755.
97. Schachna L., Medsger T.J., Dauber J., et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006, 54:3954-3961.
98. Mandel J., Mark E.J., Hales C.A. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000, 162:1964-1973.